ClinicalTrials.gg
RecruitingNCT06055959ziMyGUpdated Nov 5, 2026

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

A Phase 2/3 interventional study of Zilucoplan in Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL. Recruiting at 9 sites in 5 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Nov 5, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Myasthenia Gravis by UCB S.A. — 5 open to participants now, 7 under way, 5 of them phase 3. Myasthenia Gravis · UCB S.A..

Planned enrollment
17th of 18
8 · median 45
Started
2024
with 4 others
Phase 2/3
2 of 18
1 open now
Registered
10th of 18
by date

Among the 18 studies in Myasthenia Gravis by UCB S.A., this one is the 17th largest by planned enrollment, is one of 5 that started in 2024, is one of 2 in phase 2/3, and was the 10th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

5 of the 18 studies in Myasthenia Gravis by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Myasthenia Gravis by UCB S.A., or all of them as a file.
02

Study summary

The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

Keywords

  • RA101495
  • gMG
  • generalized myasthenia gravis
  • zilucoplan
  • pediatric
  • MG0014
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

United States of America (USA) specific inclusion criterion:

- Participant must be 12 to \<18 years of age at the time of signing the /assent according to local regulation

Rest of world (ROW) specific inclusion criterion:

- Participant must be 2 to \<18 years of age at the time of signing the Informed consent/assent according to local regulation

Global inclusion criteria:

  • Participant has a diagnosis of generalized myasthenia gravis (gMG) confirmed by a prior positive serologic test result to acetylcholine receptor (AChR) prior to Screening
  • Participant meets the criteria as defined by the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification II to IV at Screening
  • Participants with gMG, including:
  • An MG-activities of daily living (MG-ADL) total score of 6 or more in adolescents from 12 years to \<18 years of age at Screening
  • Documented weakness in at least 1 limb, neck, or bulbar muscle in children from 2 years to \<12 years of age at Screening (does not apply to US)
  • Documented vaccination against meningococcal infections within 3 years prior to study start. If not fully vaccinated, participants must receive appropriate prophylactic antibiotic treatment until at least 2 weeks after the initial dose of vaccine(s)

Exclusion criteria

Exclusion Criteria:

  • Participant has known positive serology for muscle-specific kinase
  • Participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's ability to participate in this study
  • Participant has had a thymectomy within 6 months prior to Baseline
  • Participant has minimal Manifestation Status of MG based on the clinical judgement of the Investigator
  • Current or recent systemic infection within 2 weeks prior to Baseline or infection requiring intravenous antibiotics within 4 weeks prior to Baseline
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Zilucoplan Arm

    Study participants will receive zilucoplan in pre-defined dose based on their weight.

    Drug: Zilucoplan

Interventions

  • Zilucoplan will be administered subcutaneously to pediatric study participants.

    Also known as: RA101495

06

What researchers measure

Primary outcomes

  1. Plasma concentrations of zilucoplan (ZLP) sampled at Week 4 (Day 29)

    Blood samples will be collected for measurement of plasma concentrations of ZLP on Day 29 predose.

    Time frame: Week 4 (Day 29)

  2. Change from Baseline in sheep red blood cell (sRBC) lysis at Week 4 (Day 29)

    Samples for measurement of sRBC lysis will be collected on Day 29 predose.

    Time frame: Week 4 (Day 29)

  3. Change from Baseline in complement component 5 (C5) levels at Week 4 (Day 29)

    Samples for measurement of C5 will be collected on Day 29 predose.

    Time frame: Week 4 (Day 29)

Secondary outcomes

  1. Occurence of treatment-emergent adverse events (TEAEs) during the course of the study

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From Baseline (Day 1) to Safety-Follow-Up Visit (up to Week 15)

  2. Occurrence of treatment-emergent serious adverse events (TESAEs)

    A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death Is life-threatening Requires inpatient hospitalization or prolongation of existing hospitalization Results in persistent disability/incapacity Is a congenital anomaly/birth defect Important medical events

    Time frame: From Baseline (Day 1) to Safety-Follow-Up Visit (up to Week 15)

  3. Occurrence of TEAEs leading to permanent withdrawal of investigational medicinal product (IMP)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. AEs leading to permanent withdrawal of study medication.

    Time frame: From Baseline (Day 1) to Safety-Follow-Up Visit (up to Week 15)

  4. Occurrence of treatment-emergent infections

    Percentage of participants who experienced treatment-emergent infections as adverse events. An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

    Time frame: From Baseline (Day 1) to Safety-Follow-Up Visit (up to Week 15)

  5. Occurrence of antidrug antibody (ADA) and anti- polyethylene glycol (PEG) antibodies at Week 4 (Day 29)

    ADA and anti-PEG antibodies will be evaluated in serum samples.

    Time frame: Week 4 (Day 29)

  6. Change in MG-activities of daily living (MG-ADL) score from Baseline to Week 4 (Day 29).

    The MG-ADL score is an 8-item patient-reported outcome (PRO) instrument. The MG-ADL targets symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The item responses are scored from 0 to 3, and the total score of MG-ADL is the sum of the 8 items and ranges from 0 to 24, with a higher score indicating more disability.

    Time frame: Week 4 (Day 29)

  7. Change in Quantitative MG (QMG) score from Baseline to Week 4 (Day 29)

    QMG score is a standardized and validated quantitative strength scoring system that was developed specifically for MG. The QMG total score is obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3). The score ranges from 0 to 39, with lower scores indicating lower disease activity.

    Time frame: Week 4 (Day 29)

  8. Myasthenia Gravis Foundation of America Post-Interventional Status (MGFA-PIS) at Week 4 (Day 29)

    The MGFA-PIS is a physician-determined assessment of clinical symptoms of MG after initiation of MG specific therapy. For the purpose of the current study, Minimal Manifestation will be determined at each scheduled time point after treatment initiation (rather than after 1 year). Change in status (improved, unchanged, worse, exacerbation, or died of MG) will also be determined.

    Time frame: Week 4 (Day 29)

  9. Change in Pediatric Quality of Life Inventory (PedsQoL), Version 4 domain scores from Baseline to Week 4 (Day 29)

    The PedsQoL generic core scale (Version 4) is a validated instrument that is suitable for use with pediatric populations. PedsQoL generic core scales assess Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning. The scale has 23 items with a score range of 0 to 4. Following transformation, the score range of each domain as well as the total score is 0-100 with higher scores indicating higher HRQoL.

    Time frame: Week 4 (Day 29)

07

Study locations

5 of 9 sites recruiting
  • Mg0014 50168
    Chicago, Illinois 60611, United States
    Withdrawn

    Not enrolling at this site.

  • Mg0014 50574
    Denton, Texas 76208, United States
    Withdrawn

    Not enrolling at this site.

  • Mg0014 40144
    Milan, Italy
    Recruiting
  • Mg0014 40774
    Katowice, Poland
    Recruiting
  • Mg0014 40218
    Warsaw, Poland
    Active, not recruiting

    Not enrolling at this site.

  • Mg0014 20104
    Seoul, South Korea
    Withdrawn

    Not enrolling at this site.

  • Mg0014 20220
    Seoul, South Korea
    Recruiting
  • Mg0014 40735
    Glasgow, United Kingdom
    Recruiting
  • Mg0014 40736
    London, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2024 (actual). Primary completion is estimated for May 2027, 30 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Nov 2026 → May 2027 and completion Dec 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2023
First posted
Sep 28, 2023
StartActual
Oct 16, 2024
Primary completionEst.
May 12, 2027was Nov 2026
CompletionEst.
Jun 22, 2027was Dec 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Mg0014 50574 · Denton, United States
Show 1 removed
  • Mg0014 50574 · Flower Mound, United States
Oct 2, 2026
Primary completion
Nov 16, 2026→May 12, 2027
Nov 5, 2026
Study completion
Dec 25, 2026→Jun 22, 2027
Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    Primary completion Nov 16, 2026→May 12, 2027
    Study completion Dec 25, 2026→Jun 22, 2027
    + 1 other change: verification date
  2. Oct 2, 2026
    1 site added, 1 site removed
    Show site
    • Mg0014 50574 · Denton, United States
    Show 1 removed
    • Mg0014 50574 · Flower Mound, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06055959
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Oct 16, 2024
Primary completion
May 12, 2027 (estimated)
Completion
Jun 22, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

UCB Cares
Contact
ucbcares@ucb.com
+18445992273 (USA)
UCB Cares
Contact
001 844 599 2273
UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zilucoplan

Start the discussion